A Multigene Assay Is Prognostic of Survival in Patients with Early-Stage Lung Adenocarcinoma

Purpose: Clinical staging does not adequately risk stratify patients with early stage non–small cell lung cancer. We sought to generate a real-time PCR (RT-PCR)–based prognostic model in patients with early stage lung adenocarcinoma, the dominant histology of lung cancer in the United States. Experimental Design: We studied gene expression of 61 candidate genes in 107 patients with completely surgically resected lung adenocarcinoma using RT-PCR. We used crossvalidation methods to select and validate a prognostic model based on the expression of a limited number of genes. A risk score was generated based on model coefficients, and survival of patients with high- and low-risk scores were analyzed. Results: We generated a four-gene model based on expression of WNT3a, ERBB3, LCK, and RND3. Risk score predicted mortality better than clinical stage or tumor size (adjusted hazard ratio, 6.7; 95% confidence interval, 1.6-28.9; P = 0.001). Among 70 patients with stage I disease, 5-year overall survival was 87% among patients with low-risk scores, and 38% among patients with high-risk scores (P = 0.0002). Among all patients, 5-year overall survival was 62% and 41%, respectively (P = 0.0054). Disease-free survival was also significantly different among low- and high-risk score patients. Conclusions: This multigene assay predicts overall and disease-free survival significantly better than clinical stage and tumor size in patients with early stage lung adenocarcinoma and performs especially well in patients with stage I disease. Prospective clinical trials are needed to determine whether high-risk patients with stage I disease benefit from adjuvant chemotherapy.

[1]  Biao He,et al.  Wnt signaling in lung cancer. , 2005, Cancer letters.

[2]  N. Hanna A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer , 2008 .

[3]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[4]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[5]  L. Leslie,et al.  A decade of progress. , 1969, Minnesota medicine.

[6]  Jiang Gui,et al.  Penalized Cox regression analysis in the high-dimensional and low-sample size settings, with applications to microarray gene expression data , 2005, Bioinform..

[7]  H. Wakelee,et al.  Adjuvant Chemotherapy of Stage I Non-small Cell Lung Cancer in North America , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  Igor Jurisica,et al.  Three-gene prognostic classifier for early-stage non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Liotta,et al.  Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. , 2002, Cancer research.

[10]  Alexandre Pelzer,et al.  Small G‐protein RhoE is underexpressed in prostate cancer and induces cell cycle arrest and apoptosis , 2005, The Prostate.

[11]  Michael Thomas,et al.  Identification of metastasis-associated receptor tyrosine kinases in non-small cell lung cancer. , 2005, Cancer research.

[12]  L. Dominioni,et al.  Stage I nonsmall cell lung carcinoma , 2000, Cancer.

[13]  M. Tyers,et al.  Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. , 2002, Cancer research.

[14]  Mee Young Park,et al.  L1‐regularization path algorithm for generalized linear models , 2007 .

[15]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[16]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[17]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[18]  Eric R. Ziegel,et al.  The Elements of Statistical Learning , 2003, Technometrics.

[19]  Clinical Characteristics and Survival of Patients with Surgically Resected, Incidentally Detected Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[21]  R. Tibshirani Regression Shrinkage and Selection via the Lasso , 1996 .

[22]  M. You,et al.  Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. , 2002, Neoplasia.

[23]  Yi Zhang,et al.  Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. , 2006, Cancer research.

[24]  D. Botstein,et al.  Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[26]  O. Stoeltzing,et al.  Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer , 2000, British Journal of Cancer.

[27]  M. Segal Microarray gene expression data with linked survival phenotypes: diffuse large-B-cell lymphoma revisited. , 2006, Biostatistics.

[28]  Lu Zhang,et al.  Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays , 2006, BMC Genomics.

[29]  K. Torgersen,et al.  Lck is required for stromal cell-derived factor 1 alpha (CXCL12)-induced lymphoid cell chemotaxis. , 2002, Blood.

[30]  M. D. den Bakker,et al.  A critical appraisal of prognostic and predictive factors for common lung cancers , 2006, Histopathology.

[31]  D. Harpole,et al.  Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence , 1995, Cancer.

[32]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .